logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Tentatively Approves Supernus Pharma's Epilepsy Drug Supernus

Supernus Pharmaceuticals, Inc (SUPN: Quote), a developer of products to treat central nervous system, Monday said it received a tentative approval letter from the Food & Drug Administration or FDA for its epilepsy drug Trokendi XR. The product is tentatively approved for use as recommended in the submitted and agreed-upon labeling. Trokendi XR formerly known as SPN-538 is a novel once-daily extended release formulation of topiramate.

"We will now submit the "Request for Final Approval" letter to the FDA based on which we expect to receive Final Approval and then launch our product, as anticipated, in the third quarter of 2013," said Jack Khattar, chief executive officer.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Anadarko Petroleum Corp (APC) on Monday reported a wider-than-expected loss for the first quarter, crippled mostly by lower commodity prices. General Motors has priced the new 2016 Chevrolet Volt plug-in hybrid at $33,995, including delivery charges. That's almost $1,200 less than the 2015 model. Volt's price can go as low as $26,495 after the full federal tax credit of $7,500. In California, customers can buy the new Volt for as low as... McDonald's said it would restructure its business to focus more on franchises, and would recast its market segments and cut costs, as the fast food giant grapples with weak global sales.
comments powered by Disqus
Follow RTT